Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

European Commission Approves Upadacitinib for Psoriatic Arthritis & Ankylosing Spondylitis

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2021

In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.

FDA Approves New Rituximab Biosimilar & Anakinra to Treat a Rare Disease

Michele B. Kaufman, PharmD, BCGP  |  February 2, 2021

The FDA has approved anakinra to treat a rare autoinflammatory disease, deficiency of interleukin 1 receptor antagonist. The administration also approved a new rituximab biosimilar, Riabni, for multiple indications.

A High HAQ at Baseline in Early RA Is a Bad Sign

Arthritis & Rheumatology  |  January 26, 2021

In this study, Fatima et al. analyzed how well the Health Assessment Questionnaire (HAQ) disability index predicts future all-cause mortality in patients with early RA (i.e., with a symptom duration of less than one year). A total of 1,724 patients with early RA were included. The researchers found that a higher HAQ score and Disease Activity Score at one year were significantly associated with all-cause mortality.

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Vanessa Caceres  |  January 25, 2021

In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.

The Psychosocial Toll of COVID-19

Thomas R. Collins  |  January 25, 2021

Experts discussed the heavy toll the pandemic has taken on patients and clinicians, with many patients in need of mental health support and others in need of rehabilitation.

Smart, Stem Cell-Based Implants May Revolutionize the Treatment of Arthritis

Lara C. Pullen, PhD  |  January 25, 2021

Recent breakthroughs in stem cell-based treatments for arthritis may help delay joint replacement for some patients. Farshid Guilak, PhD, described the methods for creating bioartificial cartilage, its implications for inflammation, disease flare and more.

Reproductive Health, Beyond the Guidelines: Rheumatologists Must Think About Patients’ Psychosocial Needs

Mary Beth Nierengarten  |  January 25, 2021

Experts discuss how rheumatologists must consider the psychosocial aspect of care in the decision-making process for women when addressing their reproductive health needs, in addition to medication safety.

Diagnostic Drill-Down: New Research Suggests Genetic Autoinflammatory Roots

Mary Beth Nierengarten  |  January 25, 2021

Two experts discussed ongoing difficulties in diagnosing autoinflammatory disease, & promising new studies that point to possible genetic roots of autoinflammatory disease.

MRI & Axial Spondyloarthritis: Experts Discuss Controversies in the Diagnostic Evaluation of axSpA

Lara C. Pullen, PhD  |  January 25, 2021

Three experts discuss the ins and outs of using magnetic resonance imaging to diagnose axial spondyloarthritis, particularly in individuals who lack clear clinical symptoms indicative of disease.

What to Expect in State Legislatures in 2021

Joseph Cantrell, JD  |  January 25, 2021

New state legislatures face many continuing issues, including budget shortfalls, vaccine distribution problems and strained healthcare infrastructure. However, opportunities exist for significant policy wins for rheumatology, particularly on the issues of step therapy reform, telemedicine and copay accumulators.

  • « Previous Page
  • 1
  • …
  • 162
  • 163
  • 164
  • 165
  • 166
  • …
  • 816
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences